Juxiang Chen

Juxiang Chen


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
Yu'e LiuYu'e Liu
Yu'e Liu
CCChao Chen
Chao Chen
XWXinye Wang
Xinye Wang
YSyihong sun
yihong sun
JZJin Zhang
Jin Zhang
YSYufeng Shi
Yufeng Shi
Mitochondria are not only the main energy supplier but are also the cell metabolic center regulating multiple key metaborates that play pivotal roles in epigenetics regulation. These metabolites include acetyl-CoA, α-ketoglutarate (α-KG), S-adenosyl methionine (SAM), NAD+, and O-linked beta-N-acetylglucosamine (O-GlcNAc), which are the main substrates for DNA methylation and histone post-translation modifications, essential for gene transcriptional regulation and cell fate determination. Tumorigenesis is attributed to many factors, including gene mutations and tumor microenvironment. Mitochondria and epigenetics play essential roles in tumor initiation, evolution, metastasis, and recurrence. Targeting mitochondrial metabolism and epigenetics are promising therapeutic strategies for tumor treatment. In this review, we summarize the roles of mitochondria in key metabolites required for epigenetics modification and in cell fate regulation and discuss the current strategy in cancer therapies via targeting epigenetic modifiers and related enzymes in metabolic regulation. This review is an important contribution to the understanding of the current metabolic-epigenetic-tumorigenesis concept.

16 August 2010 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
CCC. Chen
C. Chen
TXT. Xu
T. Xu
JCJuxiang Chen
Juxiang Chen
JZJ. Zhou
J. Zhou
YYY. Yan
Y. Yan
SWS. Wu
S. Wu

2 June 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TXTao Xu
Tao Xu
JCJuxiang Chen
Juxiang Chen
YLYicheng Lu
Yicheng Lu
JWJohannes Ea Wolff
Johannes Ea Wolff
Background: The combination of bevacizumab and irinotecan is a new chemotherapy protocol increasingly used for recurrent malignant glioma. Results from phase II trials suggest this drug combination is beneficial to patients, but no conclusive comparisons between this and other treatment protocols have been published. Methods: We performed a systematic review and survival gain analysis of phase II studies to evaluate the efficacy and safety of bevacizumab plus irinotecan treatment. To do this, we utilized a preexisting database from which the mean overall survival and response rate of patients could be predicted. Survival gain, which characterized the influence of treatment, was defined as the difference between observed and predicted mean overall survival. Response gain was calculated similarly. Results: 741 cohorts were enrolled in the database. Among them, 282 cohorts were based on recurrent adult HGG, mean reported median overall survival was 10.96 ± 8.4 months, and mean response rate was 18.9% ± 20.5. We found that compared with other treatment protocols, bevacizumab plus irinotecan largely improved response rates (P = 0.00002) and had a possible moderate effect on overall survival time (P = 0.024). Hemorrhage, thromboembolic complications, and gastrointestinal toxicities were the most frequently reported side effects. Conclusion: The combination of bevacizumab and irinotecan might improve outcome in patients with recurrent malignant glioma. Randomized controlled trials are recommended to evaluate this treatment protocol and the additional value of irinotecan.

27 January 2011 in Cancer Science
Verified
Journal Article
Open access
PDF file
TXTao Xu
Tao Xu
QZQuan Zhou
Quan Zhou
JZJingxu Zhou
Jingxu Zhou
YHYan Huang
Yan Huang
YYYong Yan
Yong Yan
JCJuxiang Chen
Juxiang Chen
Malignant glioma is the most common adult primary brain tumor, and the mechanism of its oncogenesis is poorly understood. Growing evidence has shown that E3 ubiquitin ligases can promote tumorgenesis of glioma. CHIP is an E3 ubiquitin ligase that can induce ubiquitylation and degradation of many tumor‐related proteins, and it has been reported to act as an upstream regulator in breast cancer; however, its role in human gliomas has not been evaluated yet. In this study, the expression of CHIP in glioma tissues was studied using immunohistochemistry. CHIP expression in glioma cells was studied by real‐time RT‐PCR, western blot and double immunofluorescence staining. The role of CHIP in glioma oncogenesis was investigated by lentivirus‐mediated RNA interference (RNAi) and overexpression in vitro and in vivo. We showed CHIP expression in glioma samples was related to tumor grades, with stronger staining in high‐grade gliomas than in low‐grade gliomas. Knocking down of CHIP suppressed proliferation, colony formation of U251 and U87 glioma cells, while overexpression of CHIP resulted in enhanced proliferation and colony formation in vitro. In a nude mouse xenograft model, intratumoral injection of CHIP RNAi lentivirus significantly delayed tumor growth. In contrast, overexpression of CHIP resulted in enhanced tumor growth in vivo. After CHIP RNAi, both survivin mRNA and protein were decreased, while CHIP overexpression induced increased mRNA and protein levels of survivin. This is the first study demonstrating CHIP contributes to oncogenesis of glioma. (Cancer Sci 2011; 102: 959–966)

28 June 2011 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
MWMei Wang
Mei Wang
CCChao Chen
Chao Chen
JQJintao Qu
Jintao Qu
TXTao Xu
Tao Xu
YLYicheng Lu
Yicheng Lu
SWShenhong Wu
Shenhong Wu

14 February 2013 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SFSonghua Fan
Songhua Fan
DMDelong Meng
Delong Meng
TXTao Xu
Tao Xu
YCYuanyuan Chen
Yuanyuan Chen
JWJingkun Wang
Jingkun Wang
QLQing Lan
Qing Lan